Wealth Enhancement Advisory Services LLC Buys 43,664 Shares of Medtronic PLC $MDT

Key Points

• Wealth Enhancement Advisory Services LLC increased its stake in Medtronic by 5.4%, buying 43,664 shares to hold 855,915 shares valued at about $86.14 million (roughly 0.07% ownership).
• EVP Harry Skip Kiil sold 52,524 shares at an average price of $97.71 for about $5.13 million, reducing his position by 61.58% to 32,768 shares.
• Medtronic slightly beat quarterly expectations with $1.36 EPS on $9.02 billion revenue, set FY2026 EPS guidance of $5.62–$5.66, and declared a $0.71 quarterly dividend (3.3% yield).

Wealth Enhancement Advisory Services LLC grew its position in Medtronic PLC (NYSE:MDT - Free Report) by 5.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 855,915 shares of the medical technology company's stock after acquiring an additional 43,664 shares during the period. Wealth Enhancement Advisory Services LLC owned 0.07% of Medtronic worth $86,135,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Delos Wealth Advisors LLC bought a new position in Medtronic in the second quarter valued at about $27,000. Corundum Trust Company INC acquired a new stake in shares of Medtronic during the third quarter valued at about $27,000. Valley Wealth Managers Inc. bought a new stake in shares of Medtronic during the third quarter worth about $29,000. Board of the Pension Protection Fund acquired a new position in shares of Medtronic in the fourth quarter valued at approximately $29,000. Finally, GoalVest Advisory LLC acquired a new position in shares of Medtronic in the fourth quarter valued at approximately $29,000. Institutional investors and hedge funds own 82.06% of the company's stock.

Insiders Place Their Bets

In other news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the transaction, the executive vice president directly owned 32,768 shares of the company's stock, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.26% of the company's stock.

Analyst Ratings Changes

Several research firms recently commented on MDT. Citigroup started coverage on shares of Medtronic in a research report on Tuesday, February 3rd. They set a "buy" rating and a $117.00 target price on the stock. Leerink Partners restated an "outperform" rating and issued a $119.00 price target on shares of Medtronic in a research report on Tuesday, March 10th. Barclays reiterated an "overweight" rating and set a $118.00 price target on shares of Medtronic in a report on Wednesday, February 18th. CICC Research initiated coverage on shares of Medtronic in a research note on Friday, January 30th. They issued an "outperform" rating on the stock. Finally, Mizuho upgraded Medtronic to a "strong-buy" rating in a report on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $110.74.

Medtronic Stock Down 0.7%

Medtronic stock opened at $86.29 on Monday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33. The firm has a 50 day moving average price of $96.82 and a two-hundred day moving average price of $96.72. The firm has a market cap of $110.78 billion, a price-to-earnings ratio of 24.03, a PEG ratio of 2.21 and a beta of 0.71.

Medtronic (NYSE:MDT - Get Free Report) last posted its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating analysts' consensus estimates of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. During the same period in the prior year, the firm posted $1.38 EPS. The company's quarterly revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts predict that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be given a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.3%. Medtronic's dividend payout ratio is 79.11%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.